M&A Deal Summary |
|
---|---|
Date | 2021-10-11 |
Target | Adamas |
Sector | Life Science |
Buyer(s) | Supernus Pharmaceuticals |
Deal Type | Add-on Acquisition |
Deal Value | 450M USD |
Advisor(s) | Lazard Ltd. (Financial) Cooley (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2005 |
Sector | Life Science |
Employees | 652 |
Revenue | 608M USD (2023) |
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Supernus Pharmaceuticals was founded in 2005 and is based in Rockville, Maryland.
DEAL STATS | # |
---|---|
Overall | 3 of 3 |
Sector (Life Science) | 3 of 3 |
Type (Add-on Acquisition) | 2 of 2 |
State (California) | 1 of 1 |
Country (United States) | 3 of 3 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2020-06-09 |
US WorldMeds - CNS Portfolio
Kentucky, United States US WorldMeds LLC - CNS Portfolio (central nervous system) is involved in developing and commercializing products for the treatment of Parkinson’s disease. |
Buy | - |